Santersus SA (Switzerland), a privately held selective plasmapheresis start-up company, is excited to announce the successful conclusion of a Nucleocapture prototype elaboration and laboratory testing.
“We are extremely pleased with the remarkably successful results of preliminary laboratory testing meeting all the endpoints” said Dr. Andrew Aswani, the Medical Director of Santersus SA. “We are planning to conduct additional pre-clinical studies on large animal models in order to explore the additional therapeutic potential of our technology” added Dr. Aswani.
Dr. Dmitry D. Genkin, co-founder of Santersus SA added, "Nucleocapture possesses a wide range of therapeutic applications against various severe diseases e.g., sepsis and Acute Kidney Injury (AKI), including sepsis-induced AKI (SAKI). Acute Kidney Injury is a damage of the kidney tissue, which can sometimes result in kidney failure. The most common cause of this disease is sepsis accounting for the majority of all patients. Other causes include cardiovascular surgery, toxic drugs or surgical contrast fluids and trauma. Depending on the severity of kidney failure, the mortality rate reaches up to 80%.”